Conatus Pharmaceuticals Inc. Expected to Earn Q3 2017 Earnings of ($0.06) Per Share (CNAT)
Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) – Analysts at SunTrust Banks lowered their Q3 2017 earnings per share (EPS) estimates for shares of Conatus Pharmaceuticals in a note issued to investors on Thursday. SunTrust Banks analyst J. Boris now expects that the biotechnology company will post earnings of ($0.06) per share for the quarter, down from their prior estimate of ($0.03). SunTrust Banks also issued estimates for Conatus Pharmaceuticals’ Q4 2017 earnings at ($0.14) EPS, FY2017 earnings at ($0.53) EPS and FY2021 earnings at $2.44 EPS.
Conatus Pharmaceuticals (NASDAQ:CNAT) last issued its quarterly earnings results on Wednesday, August 2nd. The biotechnology company reported ($0.19) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.17) by $0.02. The business had revenue of $10 million during the quarter, compared to the consensus estimate of $9.33 million. During the same quarter last year, the business posted ($0.30) EPS. TRADEMARK VIOLATION WARNING: This report was first posted by American Banking News and is the property of of American Banking News. If you are reading this report on another publication, it was illegally copied and reposted in violation of international trademark and copyright law. The original version of this report can be read at https://www.americanbankingnews.com/2017/08/07/conatus-pharmaceuticals-inc-expected-to-earn-q3-2017-earnings-of-0-06-per-share-cnat.html.
A number of other research analysts have also recently commented on CNAT. Aegis restated a “buy” rating and set a $11.00 price objective on shares of Conatus Pharmaceuticals in a research note on Friday, May 5th. ValuEngine upgraded Conatus Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, May 24th. HC Wainwright restated a “buy” rating and set a $18.00 price objective on shares of Conatus Pharmaceuticals in a research note on Thursday, June 29th. Zacks Investment Research cut Conatus Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, July 11th. Finally, Stifel Nicolaus restated a “buy” rating and set a $10.00 price objective on shares of Conatus Pharmaceuticals in a research note on Thursday. Two research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $13.39.
Shares of Conatus Pharmaceuticals (CNAT) opened at 5.19 on Monday. The firm’s 50-day moving average price is $5.80 and its 200 day moving average price is $5.60. Conatus Pharmaceuticals has a one year low of $1.45 and a one year high of $9.40. The stock’s market cap is $145.85 million.
A number of hedge funds have recently made changes to their positions in CNAT. Bank of Montreal Can purchased a new stake in shares of Conatus Pharmaceuticals during the second quarter valued at $109,000. State of Wisconsin Investment Board purchased a new stake in shares of Conatus Pharmaceuticals during the second quarter valued at $115,000. Strs Ohio purchased a new stake in shares of Conatus Pharmaceuticals during the second quarter valued at $153,000. Rhumbline Advisers purchased a new stake in shares of Conatus Pharmaceuticals during the second quarter valued at $156,000. Finally, Eagle Global Advisors LLC purchased a new stake in shares of Conatus Pharmaceuticals during the second quarter valued at $156,000. 22.53% of the stock is owned by hedge funds and other institutional investors.
About Conatus Pharmaceuticals
Conatus Pharmaceuticals Inc is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease.
Receive News & Ratings for Conatus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.